Rippl Michaela, Grupp Pauline, Martini Sebastian, Müller Katharina, Tausendfreund Olivia, Schmidmaier Ralf, Drey Michael
Department of Medicine IV, LMU University Hospital, LMU Munich, Ziemssenstr. 1, 80336 München, Germany.
Department of Medicine IV, LMU University Hospital, LMU Munich, Ziemssenstr. 1, 80336 München, Germany.
Bone. 2025 Mar;192:117366. doi: 10.1016/j.bone.2024.117366. Epub 2024 Dec 6.
Bone anabolic treatment has been shown to be superior to oral bisphosphonates, especially in osteoporosis patients with a very high fracture-risk. The current German osteoporosis guideline classifies the very high 3-year fracture-risk based upon a novel fracture-risk model. As age is a severe risk-factor, we examined the distribution and associations to geriatric assessment parameters of the very high-risk group in a well-characterized cohort of community-dwelling geriatric patients.
Analyses were based on 166 patients (mean age 82 ± 6 years) taken from MUSAR (MUnich SArcopenia Registry). Fracture-risk was calculated as described in the current German guideline. Thereupon, patients were allocated to the low-/moderate (<5 %), high- (5-10 %) or very high-risk group (>10 %). Associations of geriatric assessment parameters with the group allocation to the fracture-risk group were evaluated by covariate-adjusted linear regression analysis.
80 % of the study population were at an increased fracture-risk. Besides, >50 % were allocated to the very high-risk group. Patients in the very high-risk group showed limitations in all physical performance tests (short physical performance battery (SPPB), gaitspeed, handgrip strength and chair rise test). Also, polypharmacy and a risk for malnutrition (from mini nutritional assessment short form (MNA-SF)), were present. All parameters showed significant associations with group allocation to very high-risk group.
Most of the geriatric patients are at a very high-risk for osteoporotic fractures. Also, this group presented several limitations in the comprehensive geriatric assessment highlighting the vulnerability of this group. Clinicians need to reinforce fracture-risk assessment and familiarize with treatment options.
骨合成代谢治疗已被证明优于口服双膦酸盐,尤其是在骨折风险非常高的骨质疏松症患者中。当前的德国骨质疏松症指南基于一种新型骨折风险模型对极高的3年骨折风险进行分类。由于年龄是一个严重的风险因素,我们在一个特征明确的社区居住老年患者队列中,研究了极高风险组的分布及其与老年评估参数的关联。
分析基于从慕尼黑肌肉减少症登记处(MUSAR)选取的166例患者(平均年龄82±6岁)。按照当前德国指南中的描述计算骨折风险。据此,将患者分为低/中度(<5%)、高(5%-10%)或极高风险组(>10%)。通过协变量调整线性回归分析评估老年评估参数与骨折风险组分组之间的关联。
超过80%的研究人群骨折风险增加。此外,超过50%被分配到极高风险组。极高风险组的患者在所有身体性能测试(简短身体性能测试(SPPB)、步速、握力和从椅子上起身测试)中均表现出受限。同时,存在多重用药和营养不良风险(根据简易营养评估简表(MNA-SF))。所有参数均与极高风险组的分组存在显著关联。
大多数老年患者骨质疏松性骨折风险极高。此外,该组在综合老年评估中存在若干局限性,凸显了该组的脆弱性。临床医生需要加强骨折风险评估并熟悉治疗选择。